Shares of Merck KGaA (OTCMKTS:MKKGY – Get Free Report) have been assigned a consensus recommendation of “Hold” from the six brokerages that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation.
MKKGY has been the subject of a number of recent research reports. HSBC upgraded shares of Merck KGaA to a “hold” rating in a research note on Monday, July 6th. Jefferies Financial Group started coverage on Merck KGaA in a report on Tuesday, May 26th. They set a “hold” rating on the stock. UBS Group downgraded Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Finally, Zacks Research lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th.
View Our Latest Report on MKKGY
Merck KGaA Stock Up 0.8%
About Merck KGaA
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
See Also
- Five stocks we like better than Merck KGaA
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
